{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:27:36Z","timestamp":1792794456874,"version":"4.5.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Pseudomyxoma peritonei (PMP) is a rare malignancy originating from the appendix, characterized by disseminated mucinous tumor implants on peritoneal surfaces. We examined the role of multiplatform molecular profiling to study biomarker-guided treatment strategies for this rare malignancy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A total of 54 patients with appendix-derived PMP were included in the study. Tests included one or more of the following: gene sequencing (Sanger or next generation sequencing), protein expression (immunohistochemistry), and gene amplification (C\/fluorescent in situ hybridization).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Targeted sequencing of 47 genes detected variants in KRAS (81%), GNAS (74%), SMAD4 (16%), and ATM (16%). Mutations were found at low frequencies (n=1 to 2) in APC, BRAF, PIK3CA, MLH1, and TP53. GNAS and KRAS co-occurrence was found in 87%. Protein overexpression was found in epidermal growth factor receptor (83%), cyclooxygenase-2 (73%), cMET (63%), cKIT (58%), and platelet-derived growth factor receptor alpha (58%). Immune checkpoint expression was found in 36% (programmed cell death protein 1) and 18% (programmed death-ligand 1). Surrogate markers of cell proliferation were found at low rates (TLE3 23%, TOP2A 22%), consistent with the slow-growing biology of PMP. Phosophatase and tensin homolog was intact (wild type [100%]) and positive (immunohistochemistry [80%]). Patients exhibited stable microsatellite status and mismatch repair proficiency (93%). Importantly, multidrug resistance protein expression was elevated (100% BCRP, 94% MRP1, 88% PGP). Markers for gemcitabine (RRM1), fluorouracil (TS), oxaliplatin (ERCC1), and irinotecan (TOPO1) chemosensitivities were detected at favorable rates: 93%, 87%, 77% and 65%, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Molecular profiling by multiple platforms identified potential therapies for the nontargetable KRAS-mutated population. The role of cMET-targeted therapeutics and immune checkpoint inhibitors merits further investigation. Biomarker-guided selection of cytotoxic chemotherapies may facilitate efficacy to systemic treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000376","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T12:27:48Z","timestamp":1488544068000},"page":"777-783","source":"Crossref","is-referenced-by-count":36,"title":["Appendix-derived Pseudomyxoma Peritonei (PMP)"],"prefix":"10.1097","volume":"41","author":[{"given":"Elizabeth M.","family":"Gleeson","sequence":"first","affiliation":[{"name":"Drexel University College of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Feldman","sequence":"additional","affiliation":[{"name":"Carolinas HealthCare System, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth L.","family":"Mapow","sequence":"additional","affiliation":[{"name":"Drexel University College of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn T.","family":"Mackovick","sequence":"additional","affiliation":[{"name":"Drexel University College of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine M.","family":"Ward","sequence":"additional","affiliation":[{"name":"Drexel University College of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Morano","sequence":"additional","affiliation":[{"name":"Drexel University College of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene R.","family":"Rubin","sequence":"additional","affiliation":[{"name":"Drexel University College of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbur B.","family":"Bowne","sequence":"additional","affiliation":[{"name":"Drexel University College of Medicine, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J Clin Oncol"},{"key":"R2-20230903","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/01.sla.0000152015.76731.1f","article-title":"Long-term survival following treatment of pseudomyxoma peritonei","volume":"241","author":"Miner","year":"2005","journal-title":"Ann Surg"},{"key":"R3-20230903","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/jso.21058","article-title":"Techinical aspects of cytoreductive surgery","volume":"98","author":"Kusamura","year":"2008","journal-title":"J Surg Oncol"},{"key":"R4-20230903","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.soc.2007.04.015","article-title":"Cytoreductive surgery for peritoneal malignancies\u2014development of standards of care for the community","volume":"16","author":"Esquivel","year":"2007","journal-title":"Surg Oncol Clin N Am"},{"key":"R5-20230903","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/jso.10270","article-title":"Total abdominal colectomy, pelvic peritonectomy, and end-ileostomy for the surgical palliation of mucinous peritoneal carcinomatosis from non-gynecologic cancer","volume":"83","author":"Stamou","year":"2003","journal-title":"J Surg Oncol"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1245\/s10434-007-9701-4","article-title":"Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center","volume":"15","author":"Gusani","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"R7-20230903","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/00000478-200308000-00006","article-title":"Appendiceal mucinous neoplasms: a clinicopathologic analysis of 107 cases","volume":"27","author":"Misdraji","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"R8-20230903","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/1097-0142(20010701)92:1<85::AID-CNCR1295>3.0.CO;2-R","article-title":"Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis","volume":"92","author":"Ronnett","year":"2001","journal-title":"Cancer"},{"key":"R9-20230903","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/00000478-199512000-00006","article-title":"Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to \u201cpseudomyxoma peritonei\u201d","volume":"19","author":"Ronnett","year":"1995","journal-title":"Am J Surg Pathol"},{"key":"R10-20230903","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1177\/000313481307901120","article-title":"Proposed classification of pseudomyxoma peritonei: influence of signet ring cells on survival","volume":"7","author":"Shetty","year":"2013","journal-title":"Am Surgeon"},{"key":"R11-20230903","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/01.pas.0000202039.74837.7d","article-title":"Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review","volume":"30","author":"Bradley","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"R12-20230903","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s11605-014-2726-7","article-title":"The rise in appendiceal cancer indicidence: 2000-2009","volume":"19","author":"Marmor","year":"2015","journal-title":"J Gastrointest Surg"},{"key":"R13-20230903","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1136\/jclinpath-2012-200843","article-title":"Pathology and prognosis in pseudomyxoma peritonei: a review of 274 cases","volume":"65","author":"Carr","year":"2012","journal-title":"J Clin Pathol"},{"key":"R14-20230903","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1373\/clinchem.2014.225565","article-title":"Molecular Profiling of Appendiceal Epithelial Tumors Using Massively Parallel Sequencing to Identify Somatic Mutations","volume":"60","author":"Liu","year":"2014","journal-title":"Clinl Chem"},{"key":"R15-20230903","doi-asserted-by":"crossref","first-page":"E282","DOI":"10.1002\/ijc.29245","article-title":"Genomic profile of pseudomyxoma peritonei analyzed using next-generation sequencing and immunohistochemistry","volume":"136","author":"Nummela","year":"2015","journal-title":"Int J Cancer"},{"key":"R16-20230903","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.clgc.2014.07.010","article-title":"Molecular profiling of infiltrating urothelial carcinoma of bladder and non-bladder origin","volume":"13","author":"Millis","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"R17-20230903","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000332739","article-title":"Leptin, MUC2 and mTOR in Appendiceal Mucinous Neoplasms","volume":"79","author":"Chang","year":"2012","journal-title":"Pathobiology"},{"key":"R18-20230903","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/cam4.542","article-title":"Molecular profiles of high-grade and low-grade pseudomyxoma peritonei","volume":"4","author":"Noguchi","year":"2015","journal-title":"Cancer Med"},{"key":"R19-20230903","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/PAS.0000000000000194","article-title":"Loss of SMAD4 protein expression is associated with high tumor grade and poor prognosis in disseminated appendiceal mucinous neoplasms","volume":"38","author":"Davison","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1470-2045(10)70244-8","article-title":"The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer","volume":"12","author":"Jordheim","year":"2011","journal-title":"Lancet Oncol"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2012.43.0900","article-title":"ERCC1 and RRM1: ready for prime time?","volume":"31","author":"Besse","year":"2013","journal-title":"J Clin Oncol"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1002\/cncr.26718","article-title":"Exploring biomarkers in head and neck cancer","volume":"118","author":"Langer","year":"2012","journal-title":"Cancer"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1470-2045(08)70029-9","article-title":"Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?","volume":"9","author":"S\u00e8ve","year":"2008","journal-title":"Lancet Oncol"},{"key":"R24-20230903","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nrclinonc.2014.51","article-title":"Standing the test of time: targeting thymidylate biosynthesis in cancer therapy","volume":"11","author":"Wilson","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"R25-20230903","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/jcph.765","article-title":"Precision oncology medicine: the clinical relevance of patient specific biomarkers used to optimize cancer treatment","volume":"56","author":"Schmidt","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"R26-20230903","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/jso.23538","article-title":"Celecoxib plus chemoradiotherapy for locally advanced rectal cancer: a phase II TCOG study","volume":"109","author":"Wang","year":"2014","journal-title":"J Surg Oncol"},{"key":"R27-20230903","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1158\/2159-8290.CD-11-0240","article-title":"Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors","volume":"2","author":"Sennino","year":"2012","journal-title":"Cancer Discov"},{"key":"R28-20230903","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrm1261","article-title":"Met, metastasis, motility and more","volume":"4","author":"Birchmeier","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"R29-20230903","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s00268-006-0454-1","article-title":"Mucocele of the appendix","volume":"31","author":"Ruiz-Tovar","year":"2007","journal-title":"World J Surg"},{"key":"R30-20230903","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2169\/internalmedicine.46.0079","article-title":"Pseudomyxoma peritonei occurring after an uneventful 23 years interval from appendectomy","volume":"46","author":"Taii","year":"2007","journal-title":"Intern Med"},{"key":"R31-20230903","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.canlet.2005.12.013","article-title":"COX-2 expression in pseudomyxoma peritonei","volume":"244","author":"Gatalica","year":"2006","journal-title":"Cancer Letters"},{"key":"R32-20230903","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1200\/JCO.2008.21.6796","article-title":"Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer","volume":"27","author":"Laurent-Puig","year":"2009","journal-title":"J Clin Oncol"},{"key":"R33-20230903","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/gm559","article-title":"Genome-wide mutational landscape of mucinous carcinomatosis peritonei of appendiceal origin","volume":"6","author":"Alakus","year":"2014","journal-title":"Genome Med"},{"key":"R34-20230903","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.humpath.2014.04.018","article-title":"GNAS is frequently mutated in both low-grade and high-grade disseminated appendiceal mucinous neoplasms but does not affect survival","volume":"45","author":"Singhi","year":"2014","journal-title":"Human Pathol"},{"key":"R35-20230903","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/bjc.2013.47","article-title":"Frequent GNAS mutations in low-grade appendiceal mucinous neoplasms","volume":"108","author":"Nishikawa","year":"2013","journal-title":"Br J Cancer"},{"key":"R36-20230903","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/jso.23679","article-title":"Evaluation of a New Staging Classification and a Peritoneal Surface Disease Severity Score (PSDSS) in 229 patients with mucinous appendiceal neoplams with or without peritoneal dissemination","volume":"110","author":"Esquivel","year":"2014","journal-title":"J Surg Oncol"},{"key":"R37-20230903","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1128\/MCB.24.13.5776-5787.2004","article-title":"The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-stranded breaks","volume":"24","author":"Niedernhofer","year":"2004","journal-title":"Mol Cell Biol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201808000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T03:06:24Z","timestamp":1693710384000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201808000-00009"}},"subtitle":["Molecular Profiling Toward Treatment of a Rare Malignancy"],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000376","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]}}}